Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 5735 results for technology

  1. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 26 February 2026.

    Technology appraisal guidance
    In consultation

  2. Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) (TA730)

    NICE is unable to make a recommendation on avapritinib (Ayvakit) for treating unresectable or metastatic gastrointestinal stromal tumours in adults. Blueprint Medicines will not be launching the technology in the UK and has confirmed it will withdraw its submission.

    Technology appraisal guidance
    Published
    29 September 2021

    Sections for TA730

  3. Compliance with nice-approved medicines or treatments

    Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

  4. How can digital technologies be used to increase access to, and uptake of, condom schemes?:- Can digital technologies such as web-based schemes increase access to, and uptake of, schemes among people who live in areas without a face-to-face condom scheme or who would prefer to remain anonymous?

    Question How can digital technologies be used to increase access to, and uptake of, condom schemes?:- Can digital...

    Research recommendation
    Published
    12 October 2018

  5. Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

    NICE is unable to recommend the use in the NHS of carmustine implants as an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated because no evidence submission was received from the manufacturer or sponsor of the technology. We will review this decision if the company decides to make a submission

    Technology appraisal guidance
    Published
    25 June 2008

    Sections for TA149

  6. Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (TA961)

    NICE is unable to make a recommendation on sebelipase alfa (Kanuma) for treating lysosomal lipase deficiency that is not Wolman disease in adults. The Wolman disease population was evaluated separately in NICE highly specialised technology guidance on sebelipase alfa (HST30). The cost effectiveness of the remaining non-Wolman population has not been demonstrated at this stage.

    Technology appraisal guidance
    Published
    28 March 2024

    Sections for TA961

  7. Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

    NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.

    Technology appraisal guidance
    Published
    25 June 2008

    Sections for TA148

  8. Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation

    In development Reference number: GID-IPG10416 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  9. Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]

    In development Reference number: GID-TA11201 Expected publication date:  26 February 2026

    Technology appraisal guidance
    In development

  10. Interim process and methods statement for bringing together NICE guidance (PMG47)

    This interim process and methods statement sets out the general principles guiding NICE's approach to including NICE technology appraisal recommendations in guideline topic areas. It also describes what the key changes are to existing methods and processes

  11. Leadless cardiac pacemaker implantation for bradyarrhythmias

    In development Reference number: GID-IPG10340 Expected publication date:  25 February 2026

    Interventional procedures guidance
    In development

  12. NICE encourages further research into the use of innovative technologies for the management of severe acute respiratory failure, and may review this guidance on publication of further evidence.

    Question NICE encourages further research into the use of innovative technologies for the management of severe acute respiratory...

    Research recommendation
    Published
    9 June 2015

  13. Peripheral arterial disease: diagnosis and management (CG147)

    This guideline covers diagnosing and managing peripheral arterial disease (PAD) in people aged 18 and over. Rapid changes in diagnostic methods, endovascular treatments and vascular services associated with new specialties in surgery and interventional radiology have resulted in considerable uncertainty and variation in practice. This guideline aims to resolve that uncertainty and variation.

    Clinical guideline
    Last updated
    11 December 2020
    View recommendations

    Sections for CG147

  14. Aids to support withdrawal: What is the effectiveness of equipment, technologies, practical aids and medicine formulations in supporting people to manage dose reductions, compared with usual practice?

    Aids to support withdrawal: What is the effectiveness of equipment, technologies, practical aids and medicine formulations in...

    Research recommendation
    Published
    11 May 2022

  15. Healthcare-associated infections: prevention and control (PH36)

    This quality improvement guide was produced by NICE, in partnership with Public Health England (PHE). Its aim is twofold: to reduce the risk of harm from healthcare-associated infections for patients, staff and visitors; and to reduce the costs associated with preventable infection.

    Public health guideline
    Published
    11 November 2011

    Sections for PH36